Patents by Inventor David Richard Dodds

David Richard Dodds has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20220112455
    Abstract: The present disclosure provides recombinant Staphylococcus bacterium (e.g. S. epidermidis) that are dependent on D-alanine for growth. In one aspect, the disclosure features a recombinant Staphylococcus bacterium comprising two inactivated alanine racemase genes (?alr1?alr2); and an inactivated D-alanine aminotransferase (dat) gene. In another aspect, the disclosure features a method of making the recombinant Staphylococcus bacterium.
    Type: Application
    Filed: May 14, 2021
    Publication date: April 14, 2022
    Inventors: Travis Michael Whitfill, Ming-De Deng, David Richard Dodds, Alexander Tikhonov
  • Patent number: 11041217
    Abstract: The present disclosure provides recombinant Staphylococcus bacterium (e.g. S. epidermidis) that are dependent on D-alanine for growth. In one aspect, the disclosure features a recombinant Staphylococcus bacterium comprising two inactivated alanine racemase genes (?alr1?alr2); and an inactivated D-alanine aminotransferase (dat) gene. In another aspect, the disclosure features a method of making the recombinant Staphylococcus bacterium.
    Type: Grant
    Filed: January 4, 2019
    Date of Patent: June 22, 2021
    Assignee: Azitra Inc
    Inventors: Travis Michael Whitfill, Ming-De Deng, David Richard Dodds, Alexander Tikhonov
  • Publication number: 20190256935
    Abstract: The present disclosure provides recombinant Staphylococcus bacterium (e.g. S. epidermidis) that are dependent on D-alanine for growth. In one aspect, the disclosure features a recombinant Staphylococcus bacterium comprising two inactivated alanine racemase genes (?alr1?alr2); and an inactivated D-alanine aminotransferase (dat) gene. In another aspect, the disclosure features a method of making the recombinant Staphylococcus bacterium.
    Type: Application
    Filed: January 4, 2019
    Publication date: August 22, 2019
    Inventors: Travis Michael Whitfill, Ming-De Deng, David Richard Dodds
  • Patent number: 6521445
    Abstract: This invention relates to a method for the production of (2R,3S)-3-(4-methoxyphenyl)glycidic acids and esters thereof, which are synthetic intermediates for the production of the calcium antagonist diltiazem. The method involves the stereoselective enzymatic ester hydrolysis of racemic trans-3-(4-methoxyphenyl)glycidic acid ester to yield the resolved (2R,3S) compound as the ester. Membrane reactor methods and apparatus for the conduct of this enzymatic resolution process are also disclosed herein, as is the use of bisulfite anion in the aqueous reaction phase as a means of minimizing the inhibitory effect of an aldehyde reaction by-product on the reaction's progress. The benefits of selected solvent systems from which may be obtained highly resolved ester product are also disclosed. These enriched organic solutions may be used in subsequent transformations. Alternatively, optically pure product may be obtained directly therefrom.
    Type: Grant
    Filed: April 10, 1989
    Date of Patent: February 18, 2003
    Assignee: Sepracor, Inc.
    Inventors: David Richard Dodds, Jorge Luis Lopez, Charles Melvyn Zepp, Steven Brandt